OXFORD GLOBAL

4th Annual Formulation & Drug Delivery Congress

8 - 9 May 2018 | London, UK



Day 1 Stream 1 – Large Molecule Drug Formulation

Part 1 – Proteins, Peptides, Biosimilars

- Assessing comparability for biologics
- Overcoming protein formulation challenges
- Formulation development for biosimilars
- Protein & peptide characterisation updates

Part 2 – Vaccines, Antibodies, Biotherapeutics

- Vaccine formulation developments
- Novel adjuvants for improving vaccine efficacy
- Accelerating formulation development for antibodies

Day 1 Stream 2 – Advances in Drug Delivery

- Targeted drug delivery
- Exploring various delivery routes
- Delivery of new therapeutic modalities
- Delivery of emerging biologics including mRNA, siRNA delivery, DNA delivery
- Drug delivery to the brain
- Viral vectors as delivery systems

New to 2018! Day 1 Stream 3 – Drug Delivery Devices

- Patient centered integrated device implementation
- Needle-free delivery systems
- Devices development - continuous administration of drugs
- Human Factors, Behavioural Design And Human Centred Design For Delivery Device Development

Day 2 Stream 1 – Small Molecule Drug Formulation

- Recent progress in amorphous solid dispersions
- Advanced formulation strategies & methods for small molecules
- Overcoming key formulation challenges for small molecules
- Nano-formulations
- Quality-by-Design approaches
- Excipients for small molecule formulation

New to 2018! Day 2 Stream 2 – Bioanalysis and Stabilisation

- Bioanalytical development for large molecules
- Analytical development for novel therapeutics
- Analytical strategies for novel proteins and antibodies
- Stability testing and stability approaches for biologics
- Stability testing for particles
- Understanding the characterisation of large molecules
- Novel analytical tools to analyse particles

Benefits to Attending

✓ **Hear from and meet with the key innovators in formulation & drug delivery.** 2018 attendees include: CTO, Teva Pharmaceuticals; Senior Scientific Director, Novo Nordisk; Senior Director, Pfizer

✓ **Discover collaborative solutions to large and small molecule formulation development.** The congress brings together key opinion leaders to discuss protein formulation challenges, biosimilars formulation development and advanced formulation strategies for small molecules

✓ **Discuss the latest advances in drug large and small molecule drug delivery** including targeted delivery updates, exploring various delivery routes and mRNA delivery

✓ **New to 2018! In line with current industry trends, the 2018 programme will take an in depth look at bioanalysis, stabilisation and delivery device updates**. Learn more about stability testing, particle-size analysis and needle-free delivery systems

✓ **Unparalleled networking opportunities.** This two-day congress offers dedicated networking breaks creating an interactive platform for scientific discussions and 1-1 meetings. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion

✓ Co-located with the **3rd Annual Inhalation & Respiratory Drug Delivery Congress**

Complimentary Webinars 2018

1. **Nano-based Oncological Drug Delivery – 20th Feb 2018, 10.30a.m. GMT**
   Register here
2. **Novel Oral Formulation And Drug Delivery – 27th Feb 2018, 2.30 p.m. GMT**
   Register here
3. **Large Molecule Formulation and Analytical Development – 7th Mar 2018, 10.30 a.m. GMT**
   Register here

2018 Speakers Include:

Aktham Aburub
Eli Lilly & Company

Svend Ludvigsen
Novo Nordisk

Florence Arvis
Sanofi

Meet Senior Decision Makers

Over 350 VPs, Directors and Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:

Formulation Development
Formulation Sciences
Biologics Development

Drug Delivery Technologies
Drug Delivery Innovation
Device Development

Stability Sciences
Analytical Sciences
Stability Testing

Sustained Delivery
Small Molecule Development
Nanotechnology

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Pre-Formulation Development
Formulation Development
Oral Dosage Forms

Drug Delivery System Design
Drug Delivery Automation
Oral Drug Delivery Services

Analytical Development
Analytical Characterisation
Particle Sizing

Solid State Chemistry
Bioavailability Enhancement
Feasibility Studies

For booking details & registration fees please refer to the last page or visit:
http://www.formulation-congress.com/marketing/

2018 Confirmed Speakers:

- Menashe Levy, Chief Technology Officer and Vice President, Global R&D, Teva Pharmaceuticals
- Mano Manoharan, Senior Vice President Innovation Chemistry, Alnylam Pharmaceuticals
- Svend Ludvigsen, Senior Scientific Director, Novo Nordisk
- Advait Badkar, Senior Director, Pfizer
- René Holm, Head and Scientific Director, Liquids & Parenterals, The Janssen Pharmaceutical Companies of Johnson & Johnson
- Beate Bittner, Portfolio Strategy Director, Roche
- Bernardo Perez-Ramirez, Senior Scientific Director, Global Pharmaceutics Development Biologics, Sanofi
- Martinus Capelle, Scientific Director, Head Formulation Science & Technology, Janssen Vaccines & Prevention B.V
- Sushma Kommareddy, Associate Director, Formulation Development, Takeda Pharmaceuticals
- Giustino Di Pretoro, Associate Director, Janssen Research & Development, PDMS
- Florence Arvis, Head of Formulation Unit, Sanofi-Pasteur
- Florian Turk, Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals
- Jérôme Mantanus, Head of Formulation & Process Characterization, UCB
- Thorsten Lorenz, Head Developability Assessment, Novartis Pharma AG
- Britta Furtmann, Lab Head Formulation Development, Pharmaceutical Development Biologics, Sanofi
- Ahmed Besheer, Senior Fellow, Group Head NBE Formulation Development, Novartis
- Jaymin Shah, Senior Research Fellow and Team Leader, Pharmaceutical Sciences, Pfizer
- Margaret Landis, Associate Research Fellow, Pfizer
- Heather Flores, Principal Scientist, Genentech
- Lennart Lindfors, Principal Scientist, AstraZeneca
- Paresh N. Vadgama, Principal Scientist - Formulation & Analytical Development, Glenmark Pharmaceuticals S. A.
- Aditya Tatavarti, Principal Scientist, MSD
- John Paul Savaryn, Senior Scientist, DMPK, AbbVie
- Aktham Aburub, Senior Research Advisor, Eli Lilly and Company
- Axel Becker, Senior Scientist, Merck KGaA
- Michael Keller, Senior Principal Scientist, Pre-Clinical CMC, Pharma Research and Early Development, Roche Innovation Centre
- Christer Tannergren, Associate Principal Scientist in Biopharmaceutics, AstraZeneca
- Marianne Ashford, Senior Principal Scientist, Drug Targeting, AstraZeneca
- Cedric Gysel, Staff Device Engineer, Janssen Pharmaceuticals
- Paolo Avalle, ACDS-PAT, MSD
- Alamelu Banda, Scientist - Small Molecule Pharmaceutical Science, Genentech Research and Early Development
- Duncan Craig, Professor of Drug Delivery and Director, University College London
- Karsten Mäder, Full Professor and Head of the Pharmaceutics and Biopharmaceutics, Martin-Luther-University Halle
- Amir Tamiz, Amir Tamiz, Director, Division of Translational Research, National Institute of Neurological Disorders and Stroke, National Institute of Health
- Constantin-C. Coussios, Statutory Chair of Biomedical Engineering, University of Oxford
- Moein Moghimi, Professor of Pharmaceutics and Nanomedicine, School of Pharmacy, Newcastle University
- Anne Juppo, Professor, Division of Pharmaceutical Chemistry & Technology, University of Helsinki
- Dennis Douroumis, Director of Centre for Innovation in Process Engineering and Research, University of Greenwich

2018 Formulation & Drug Delivery and Inhalation & Respiratory Drug Delivery Congress Sponsors

Platinum Sponsor:

Bronze Sponsor:

Event Sponsors:

For more information please contact marketing@oxfordglobal.co.uk

4th Annual Formulation & Drug Delivery Congress
Day One – 8th May 2018

	4th Annual Formulation & Drug Delivery Congress		
08.30 – 09.00	**Co-Located Keynote Address:** **Recent Advancements In Teva's Formulation & Drug Delivery Research** **Menashe Levy, Chief Technology Officer and Vice President, Global R&D, Teva Pharmaceuticals**		
	Large Molecule Drug Formulation	**Advances In Drug Delivery**	**Drug Delivery Devices**
09.00 – 09.30	**Stream Keynote Address:** **Optimising Formulation Of Peptides And Proteins For Delivery, Stability And Optimal PK** • Formulation design of insulins, examples • Formulation of smaller proteins for subcutaneous injection: balance stability and pharmacokinetic properties • Accelerating insulin absorption to the blood stream • Rapid acting Insulins for injection are they fitted for pump infusion? **Svend Ludvigsen, Senior Scientific Director, Novo Nordisk**	**Stream Keynote Address:** **Targeted Delivery Of Nucleic Acid Therapeutics: From Principles To Patients** **Mano Manoharan, Senior Vice President Innovation Chemistry, Alnylam Pharmaceuticals**	**Stream Keynote Address:** **Improving Patient Convenience: Challenges And Opportunities In Drug Product Development** • Patient centered integrated device implementation in early development • Analytical tools and workflows to assess device ability potential of therapeutic proteins **Bernardo Perez-Ramirez, Senior Scientific Director Global Pharmaceutics Development Biologics, Sanofi**
09.30 – 10.00	**Solution Provider Presentation** ADARE Pharmaceuticals™		
10.00 – 11.20	**Morning Coffee & Refreshments, One to One Meetings x3, Poster Presentation Sessions**		
11.20 – 11.50	**Vaccine Formulation Development** **Sushma Kommareddy, Associate Director, Formulation Development, Takeda Pharmaceuticals**	**Targeted Drug Delivery – Targeting Tumours For Oncology** **Advait Badkar, Senior Director, Pfizer**	**Development Of Slow Delivery Devices For Antibodies** Invitation to: **Serkan Oray, Senior Director, Device & Technology, UCB**
11.50 – 12.20	**Protein-Excipient Interactions Evaluated Via NMR Studies In Multi-Dose Formulations: Influence On Antimicrobial Efficacy And Potential Study Approach** • Preservatives are excipients essential for multi-dose formulations to prevent microbial growth, however, they are known to interact with non-ionic surfactants like polysorbate and potentially with active pharmaceutical ingredients • In the current study those interactions were successfully analyzed via NMR and correlated to the stability and antimicrobial activity of the formulations • As an outcome, NMR is suggested as a powerful tool to support the development of multi-dose formulations using minimal testing volumes **Britta Furtmann, Lab Head Formulation Development, Pharmaceutical Development Biologics, Sanofi**	**Big Molecules And Small Particles** • Composition and Preparation of mRNA Lipid Nanoparticle (LNPs) • Small angle scattering characterization of LNPs - core and surface structures • Impact of LNP surfaces on their biological efficiency (in vitro cell and in vivo) **Lennart Lindfors, Principal Scientist, AstraZeneca**	**Device Development For Biosimilars – Pre-Filled Syringes And Injection Devices** **Florian Turk, Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals**

For more information please contact marketing@oxfordglobal.co.uk

4th Annual Formulation & Drug Delivery Congress
Day One – 8th May 2018

	4th Annual Formulation & Drug Delivery Congress		
	Large Molecule Drug Formulation	**Advances In Drug Delivery**	**Drug Delivery Devices**
12.20 – 12.50	**Solution Provider Presentation** **For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk**	**RESERVED FOR CAPSUGEL**	**Solution Provider Presentation** **For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk**
12.50 – 13.50	**Lunch, Poster Presentation Sessions**		
13.50 – 14.20	**To Trp Or Not To Trp: Screening For Trp Oxidation During Monoclonal Antibody Formulation Development** **Sreedhara Alavattam, Senior Group Leader and Principal Scientist, Genentech**	**Addressing The Unmet Needs And Perspectives For Parenteral Controlled Release** **Karsten Mäder, Full Professor and Head of the Pharmaceutics and Biopharmaceutics, Martin-Luther-University Halle**	**Human Factors, Behavioural Design And Human Centred Design For Delivery Device Development** **Cedric Gysel, Staff Device Engineer, Janssen Pharmaceuticals**
14.20 – 14.50	**Solution Provider Presentation** **For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk**	**Solution Provider Presentation** innocore pharmaceuticals	**Solution Provider Presentation** **For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk**
14.50 – 15.20	**Vaccine Formulation: Key Challenges** • Multi valences • Compatibility with adjuvant • Process yield **Florence Arvis, Head of Formulation Unit, Sanofi-Pasteur**	**Industry-Facing Research In Small Molecule Delivery** **Duncan Craig, Professor of Drug Delivery and Director, University College London**	**Design Control And Risk Management Strategies For Combination Products** Invitation to: **Richard Wedge, Director Design Control Implementation, Pfizer**
15.20 – 16.20	**Afternoon Coffee & Refreshments, Poster Presentation Sessions**		
16.20 – 16.50	**Pre-Formulation Assessment During Lead Selection Of Biologics** • The talk will provide an overview of the Developability Assessment concept at Novartis and the integration of a preformulation workpackage prior to the selection of the final molecule • The presentation will outline the application of high-throughput automation and analytical methods • Case studies of recent projects will present the importance of applying such screens early in the process of biologics development **Thorsten Lorenz, Head Developability Assessment, Novartis Pharma AG**	**Ultrasound-Enhanced Oncological Delivery Of Antibodies, Viruses, Oligonucleotides And Other Nanomedicines** **Constantin-C. Coussios, Statutory Chair of Biomedical Engineering, University of Oxford**	**3D Printed Microneedle Patches For Transdermal Delivery** **Dennis Douroumis, Director of Centre for Innovation in Process Engineering and Research, University of Greenwich**

4th Annual Formulation & Drug Delivery Congress
Day One – 8th May 2018

	Large Molecule Drug Formulation	Advances In Drug Delivery	Drug Delivery Devices
16.50 – 17.20	**Formulation And Analytical Challenges In The Delivery Of First-In-Human Dose Of Bispecific Antibodies** **Paresh N. Vadgama, Principal Scientist - Formulation & Analytical Development, Glenmark Pharmaceuticals S. A.**	**Nanoparticle-Mediated Drug Delivery – Improve The Therapeutic Potential of Drugs** **Marianne Ashford, Senior Principal Scientist, Drug Targeting, AstraZeneca**	**Workshop** **The Workshop Aims To Provide Guidance And Advice On How To Successfully Incorporate Human Factors Into Prefilled Devices** • Understanding of Human Factors for pre-filled syringes in the context of the whole user interface; including instructional material, training and packaging. • Applying Human Factors in pre-filled devices to enable delivery of high quality, market leading devices. • Ensuring balance safety, usability and commercial success
17.20 – 17.50	**The Significance Of Absorption On Filter Membranes For Biologics Drug Product Development** **Ahmed Besheer, Senior Fellow, Group Head NBE Formulation Development, Novartis**	**Bioconjugated Solid Lipid Nanoparticles For Cancer Treatment** **Dennis Douroumis, Director of Centre for Innovation in Process Engineering and Research, University of Greenwich**	*Delegates are welcome to attend the co-located presentations*
17.50 – 18.20	**Think Tank Round Table Discussion** **Table 1 – Advances In Long Acting Injectables** Invitation to: Menashe Levy, Chief Technology Officer and Vice President, Global R&D, Teva Pharmaceuticals **Table 2 – Large Molecule Drug Formulation** Invitation to: Svend Ludvigsen, Senior Scientific Director, Novo Nordisk **Table 3 – Advances In Drug Delivery & Device Updates** Invitation to: Advait Badkar, Senior Director, Pfizer **Table 4 – Small Molecule Drug Formulation** Invitation to: René Holm, Head and Scientific Director, Liquids & Parenterals, The Janssen Pharmaceutical Companies of Johnson & Johnson **Table 5 – Aggregation and Sub-visible Particle Formation Challenges for High Concentration Biopharmaceutical Formulations** CONFIRMED: Tanvir.Tabish, Head of Drug Product Development for Gene Therapy and Coagulation Factors, Shire		
18.20	**Networking Drinks and End of Day 1**		

4th Annual Formulation & Drug Delivery Congress
Day Two – 9th May 2018

	4th Annual Formulation & Drug Delivery Congress	
08.30 – 09.00	**Co-Located Keynote Address:** **Advances In Small Molecule Formulation Development** **René Holm, Head and Scientific Director, Liquids & Parenterals, The Janssen Pharmaceutical Companies of Johnson & Johnson**	
	Small Molecule Drug Formulation	**Large Molecule Drug Delivery**
09.00 – 09.30	**Stream Keynote Address:** **A Risk Based Approach To Bridging Throughout Product Development** • Changes during product development are almost inevitable • In vivo bridging studies are costly and time consuming • A systematic approach to assessing the in vivo risk associated with CMC related changes is presented. The relative bioavailability risk assessment takes into account the type/level of change, physicochemical properties, in silico modeling and in vitro drug product performance among other factors **Aktham Aburub, Senior Research Advisor, Eli Lilly and Company**	**Stream Keynote Address:** **Subcutaneous Administration Of Biologics** **Beate Bittner, Portfolio Strategy Director, Roche**
09.30 – 10.00	**Oral Delivery Of Live Bio-Therapeutics: Drug Product Development For FIM Studies** • Key CMC considerations for the development of an LBP product. • Critical factors affecting time-lines when outsourcing GMP manufacturing activities of LBP drug products • Incorporating Quality (systems and regulations) into early phase dosage form design of LBP drug products **Mike Frodsham, Head of Pharmaceutical Development, Quay Pharma** Quay Pharma	**Solution Provider Presentation** **For sponsorship opportunities please contact** **sponsorship@oxfordglobal.co.uk**
10.00 – 11.00	**Morning Coffee & Refreshments, Poster Presentation Sessions**	
11.00 – 11.30	**Janssen's Vision And Strategy On Continuous Manufacturing** **Giustino Di Pretoro, Associate Director, Janssen Research & Development, PDMS**	**Delivery Of New Therapeutic Modalities (TBC)** Invitation to: **Jaymin C. Shah, Research Fellow and Pharmaceutical Sciences Team Leader, Pfizer Research and Development**
11.30 – 12.00	**Solution Provider Presentation** **For sponsorship opportunities please contact** **sponsorship@oxfordglobal.co.uk**	**Solution Provider Presentation** **For sponsorship opportunities please contact** **sponsorship@oxfordglobal.co.uk**

4th Annual Formulation & Drug Delivery Congress
Day Two – 9th May 2018

	Small Molecule Drug Formulation	Bioanalysis And Stabilisation
12.00 – 12.30	**Exploring The Dark Side Of Continuous Manufacturing – Business And Scientific Challenges Behind 1st Implementation** • Business case challenges • Technology platform • Control Strategy requirements **Jérôme Mantanus, Head of Formulation & Process Characterization, UCB**	**A Disruptive Technology In Active Targeting And Delivering Of Macromolecules Across Biological barriers** • A new and simple concept in active targeting with a phage derived peptide • Targeting two independent receptors with self-assemblies of the same phage-derived peptide • Peptide complexation with nucleic acids (e.g., siRNA) and functional siRNA delivery to target cells with unprecedented safety • In vivo proof of rapid targeting the biological barriers (e.g., the blood-brain-barrier) with successful delivery of biomacromolecules **Moein Moghimi, Professor of Pharmaceutics and Nanomedicine, School of Pharmacy, Newcastle University**
12.30 – 13.30	**Lunch, Poster Presentation Sessions**	
13.30 – 14.00	**Understanding And Predicting Colonic Drug Absorption Of Modified Release Formulation Candidates During Candidate Selection** **Christer Tannergren, Associate Principal Scientist in Biopharmaceutics, AstraZeneca**	**Characterization Of Biologics Using Both Standard And Novel Methodologies And Techniques (TBC)** **Martinus Capelle, Scientific Director, Head Formulation Science & Technology, Janssen Vaccines & Prevention B.V**
14.00 – 14.30	**Physical Stability Assessment of API In Amorphous Solid Dispersions: Adding More Complexity** • Differences in chemical vs physical stability aspects • Monitoring tools for physical form changes • Prediction approaches for physical stability behavior • Industry case study **Axel Becker, Senior Scientist, Merck KGaA**	**Bioanalytical Development Of Large Molecules** **John Paul Savaryn, Senior Scientist, DMPK, AbbVie**
14.30 – 15.00	**The Emerging Molecular Space of Small Molecule Therapeutics: Implications To Candidate Selection And Drug Formulation** • In attempts to drug historically "udruggable" targets, the molecular substrate for small molecule therapeutics is evolving into complex constructs. The sophisticated, enabled formulation technology potentially necessary to deliver these complex molecules will be discussed • Discussion of molecular attributes that may mitigate oral delivery risks for non-Rule of 5 compliant small molecules • Discussion of the increased use of modified release formulation and how proper candidate selection will play a role in ensuring success of this technology **Margaret Landis, Associate Research Fellow, Pfizer**	**Formulation and Analytics** **Michael Keller, Senior Principal Scientist, Pre-Clinical CMC, Pharma Research and Early Development, Roche Innovation Centre**
15.00 – 15.30	**Afternoon Coffee & Refreshments, Poster Presentation Sessions**	
15.30 – 16.00	**Pragmatic Formulation Strategies To Enable Early CNS Therapeutics Development Programs** **Amir Tamiz, Director, Division of Translational Research, National Institute of Neurological Disorders and Stroke, National Institute of Health**	**Mechanistic Understanding Of The Process Failure Modes To Scale Up A Complex Triple Combination HIV Bilayer Tablet** **Aditya Tatavarti, Principal Scientist, MSD**

For more information please contact marketing@oxfordglobal.co.uk

4th Annual Formulation & Drug Delivery Congress
Day Two – 9th May 2018

	Small Molecule Drug Formulation	Bioanalysis And Stabilisation
16.00 – 16.30	**Material Sparing Approaches To Develop Small Molecule Drug Product** • Use of miniaturized screening tools to enable rapid screening of solubility and stability enhancing polymers for amorphous formulations • Application of compaction simulation for mechanical characterization of powders and small scale simulation of dry granulation process **Alamelu Banda, Scientist - Small Molecule Pharmaceutical Science, Genentech Research and Early Development**	**Stability & Formulation Vaccine Prediction** **Olivier Brass, Senior Scientist, Research Unit Lead, Sanofi Pasteur**
16.30 – 17.00	**Atomic Layer Deposition For Making Nanocoatings Of Pharmaceuticals** **Anne Juppo, Professor, Division of Pharmaceutical Chemistry & Technology, University of Helsinki**	**Application Of Multivariate Bioanalysis In Upstream Fermentation Control** **Paolo Avalle, ACDS-PAT, MSD**
17.00 – 17.30	**The Unmet Need Of Biodegradable Parenteral Controlled Release DDS: Concept, Performance And Perspectives** **Karsten Mäder, Professor of Pharmaceutics, Martin-Luther-University Halle Wittenberg**	
17.30	**End of Conference**	

4th Annual Formulation and Drug Delivery Congress
Conference: 8-9 May 2018 London, UK
www.formulation-congress.com
HOW TO REGISTER:
FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk

Delegate Details

Please complete fully and clearly. Please photocopy for additional delegates

Title: _____Forename:_____Surname:_____

Job Title: _____

Company/Organisation:_____

Email:_____

Address:_____

_____

Postcode: _____

Country: _____

Direct Telephone _____ Direct Fax: _____

Mobile: _____ Switchboard: _____

Signature: _____

Date: _____

Registration Fees

I would like to attend: (Please tick as appropriate)

Industry Delegates *(Biopharma, Pharma or Biotech Companies)*
☐ Congress £899 plus VAT
1 day pass £599 plus VAT
☐ Day 1
☐ Day 2

Academic Delegates
☐ Congress £520 plus VAT
1 day pass £320 plus VAT
☐ Day 1
☐ Day 2

Vendor Delegates *(CROs, Consultants, Technology and Service Providers)*
☐ Congress £1,750 plus VAT
1 day pass £999 plus VAT
☐ Day 1
☐ Day 2

☐ Poster Presentation £250 plus VAT

PROMOTIONAL LITERATURE DISTRIBUTION

☐ Distribution of your company's promotional literature to all conference attendees £999 plus VAT

Documentation

I cannot attend but would like to purchase access to the following:
☐ Access to the online conference presentations £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

Terms & Conditions of Booking

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

Delegate Booking Fee
The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.
Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

Poster Presentations
Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size.

Cancellation and Curtailment
Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

More than 6 months prior	35% cancellation fee / 65% refund
Between 6 and 3 months prior	75% cancellation fee/ 25% refund
Less than 3 months prior to the event	Full cancellation fee / No refund

Data Protection
The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein.

Miscellaneous
This Agreement may not be transferred or assigned by either the Delegate or the Delegate's Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate's Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded. For promotional purposes, there may be professional photography and video production taking place during the conference. Delegates who do not wish to be filmed or recorded should advise the organisers by email to operations@oxfordglobal.co.uk, prior to the event

☐
I agree to the above Terms and Conditions

How to Pay (choose one of the following payment options)

Number of delegates:

Industry del(s) ☐ Academic dels(s) ☐ Vendor dels(s) ☐

☐ **Special Offer: 3 for 2**
Offer is only valid on the congress and for those registering at Industry or Academic rates

CREDIT CARD: ☐Visa ☐MasterCard ☐Maestro ☐Amex

Credit Card Number:
☐☐☐☐ ☐☐☐☐ ☐☐☐☐ ☐☐☐☐

Valid from: ☐☐/☐☐ Expiry Date: ☐☐/☐☐

Security code: ☐☐☐☐

Cardholders name:
_____

Signature: _____ Date: _____

☐ **PLEASE INVOICE ME:**

Invoice Address (if different from above)_____

*Please note there is a £50 plus VAT handling charge for payment via invoice